CX-038839 Omicron (XBB.1.5)

The UC Davis MIND Institute's PATH Vaccination Clinic offers COVID-19 and flu vaccines for individuals with neurodevelopmental conditions and their siblings, providing individualized, sensory-friendly care. Appointments are required, and the clinic has a nearly 100% success rate, attracting repeat families due to its positive experience.

This study explored autoantibodies in COVID-19 vaccine-related AEFIs, comparing them with other AEFIs, healthy donors, and COVID-19-exposed cases. Recruitment followed SWEDEGENE methodology, focusing on vaccines like Comirnaty, Spikevax, and Vaxzevria. Two subsets of samples were analyzed, with autoantibody detection via bead-based and ELISA assays. Positive responses were confirmed by exceeding specific thresholds or functional analyses. Sampling involved heparinized blood, and statistical analyses were conducted using SPSS and Rstudio.

UK biopharma sues US rival Moderna for infringing mRNA tech patents in Spikevax development, alleging Moderna used protected inventions despite touting speed. Moderna reported over $6bn from Spikevax in 2023.

Research!America announces 2025 Advocacy Awards recipients, recognizing leaders advancing medical and health research. Awards presented at National Academy of Sciences event on March 12, 2025.

The FDA updates mRNA COVID-19 vaccines for 2024-2025 to include KP.2 strain of Omicron JN.1 lineage, aiming for better protection. Updated vaccines available for all age groups, with specific dose recommendations based on vaccination history. Both Pfizer and Moderna confirm immediate availability.

Moderna has initiated its Phase III Nova 301 trial for mRNA-1403, a norovirus vaccine, aiming to assess efficacy, safety, and immunogenicity globally. The trial will enroll 25,000 adults, focusing on regions including the US, Canada, the UK, Japan, Australia, and South America. mRNA-1403 targets multiple norovirus genotypes and aims to prevent severe gastroenteritis, particularly in older adults.

EMA's CHMP recommended approval for 8 new medicines and extended indications for 12 others, including treatments for cancers, hemophilia, meningococcus, and biosimilars for age-related macular degeneration. Updates to COVID-19 vaccines Spikevax and Comirnaty targeting new variants were also recommended. CHMP extended indications for mpox vaccine Imvanex and others, while refusing authorization for Syfovre. Bruno Sepodes was elected as new CHMP chair, prioritizing medicine quality, safety, and efficacy.

EMA's CHMP recommended approval for 8 new medicines and extended indications for 12 drugs, including treatments for cancers, hemophilia, meningococcus, and biosimilars for age-related macular degeneration. CHMP also updated COVID-19 vaccines Spikevax and Comirnaty to target new variants. Bruno Sepodes was elected as the new CHMP chair, prioritizing medicine quality, safety, and efficacy.

EMA authorizes Bavarian Nordic's mpox vaccine Imvanex for adolescents; WHO supports single-dose use for wider reach. CHMP recommends updated mRNA COVID-19 vaccines and approves 8 new medicines, extends 11 others.

The FDA authorized updated mRNA COVID-19 vaccines targeting the KP.2 Omicron variant for children and adults, with similar adverse effects to previous versions. Additionally, an updated Novavax vaccine targeting the JN.1 Omicron subvariant was approved for those aged 12 and older.